Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD
about
Beyond fat mass: exploring the role of adipokines in rheumatic diseasesAdipokines, metabolic syndrome and rheumatic diseasesRole of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseasesRegulation of cell survival and death by pyridine nucleotidesSirtuin deacylases: a molecular link between metabolism and immunityThe role of the microbiome in rheumatic diseasesNAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophagesMetabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cellsCatastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.Proteomic and systems biology analysis of the monocyte response to Coxiella burnetii infection.Targeting of nicotinamide phosphoribosyltransferase enzymatic activity ameliorates lung damage induced by ischemia/reperfusion in ratsFK866 attenuates acute hepatic failure through c-jun-N-terminal kinase (JNK)-dependent autophagyAdipocytokines are associated with radiographic joint damage in rheumatoid arthritis.Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes.Effect of feeding status on adjuvant arthritis severity, cachexia, and insulin sensitivity in male Lewis rats.Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity.Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: a case control study.Changes in subcellular localization of visfatin in human colorectal HCT-116 carcinoma cell line after cytochalasin B treatment.Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases.Cofilin, a hypoxia-regulated protein in murine lungs identified by 2DE: role of the cytoskeletal protein cofilin in pulmonary hypertension.Plasma levels of leptin and visfatin in rheumatoid arthritis patients; is there any relationship with joint damage?NAMPT (visfatin), a direct target of hypoxia-inducible factor-2α, is an essential catabolic regulator of osteoarthritisNicotinamide Phosphoribosyltransferase in Human Diseases.Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.The role of adipokines in connective tissue diseases.Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expressionNAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responsesInhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarctionPharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.The effects of adipokines on cartilage and meniscus catabolismLife span extension and neuronal cell protection by Drosophila nicotinamidase.Visfatin/Nampt: an adipokine with cardiovascular impactNicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism.Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases.Nampt: linking NAD biology, metabolism and cancer.Visfatin: a potential therapeutic target for rheumatoid arthritis.MC-PPEA as a new and more potent inhibitor of CLP-induced sepsis and pulmonary inflammation than FK866.
P2860
Q26864855-C7287B48-AC37-4F0F-9CF8-3D45986DEAD8Q26865268-F13A9ADA-669D-43A7-91A1-DACA19B352D7Q27008359-AF42BEAB-ACB0-45E8-A25D-EED724FFA961Q27026075-6C7CE0C6-E3E2-4281-BFF3-AA38F3DCA59AQ28283588-56BB8043-BE45-4FEE-872E-14C96B823526Q28284835-AFDFDC9F-F91C-4CDB-8ECC-F691F21D5B55Q28538761-F38909B7-EF9E-42CD-9BFA-27622EE467E2Q28542558-474296E0-182B-4731-A3F1-D5D3DAC7551DQ30912415-3302BC17-B3E5-40C6-A578-6FDC552EC5DFQ31130533-1B808995-5AAB-45A5-A02E-E7E149EB3E64Q33602183-7EFABED1-E1E5-4C3E-BD04-2079C9169038Q33708531-1F07D4D5-FA28-4B88-984D-92AB4BDA54E9Q33950766-149C72A5-E486-4857-9408-259B53875715Q34103687-6DC1847A-C6BF-4B3E-9452-E9F73EF4D946Q34112904-1F25C153-1F4E-4C5A-AAE7-D15927CFB9FDQ34189534-E98D8DCB-CA8F-46E0-BD3C-B1089699C655Q34228799-33D80504-5FAE-4BF1-8279-5E0CB8D6833FQ34321550-FDD2BD10-BA8C-46D8-AACD-E8719FA8E637Q34325856-1A063A49-A0F3-4B4E-BFA9-86D7719AB647Q34446797-E036D23E-0F7E-4EE9-8CE0-C65B0C99D257Q34480694-8DCF8C89-A9C7-47FD-870D-D95FF43029F7Q35065164-A5D6646E-E60F-4529-95ED-20F76030574FQ35135460-92C7EDCD-8B72-42B3-AB4F-FF5916B76FFAQ35581515-20AC9509-FA43-4708-8AD4-2B92BB1A2291Q35860727-E97F723A-1990-4DF4-B7BE-C46FF35D896AQ36095970-E8A12F54-EE35-4B80-A76C-19354E5C95F8Q36162234-38546296-84E4-4D68-9FEB-531353C102A0Q36288116-C6EE24F5-B900-44D6-A563-BF73D851CC86Q36436005-ED7540C7-04EB-43B9-BC02-1B7159D72D6CQ36545914-8DC40631-437C-4BDB-AC86-EDAFBC80AC0AQ36579595-FCB496C3-8DCD-4B94-BF73-0AF091346BF6Q36741296-A6BEBC10-5C17-4A46-819C-99BC5ACF3F92Q36924185-C7EF1F15-F8C4-44E0-89D1-FD45763BA88FQ36970010-DA924942-872C-42A8-870B-DCEED67AACDFQ36993938-4620CE0D-30C8-4021-9629-C28500D28386Q37000257-D3F35301-16D1-4A63-9F7B-D4985CBCAD3FQ37324960-BE168C47-7C97-4512-8FDE-2C459AD66DF4Q37334248-97A659AF-DADB-444F-B3F7-E9B8A5203A20Q37690440-48C22EE2-8636-4059-9516-AAC71E04FB1EQ37691630-0856BF23-04A7-4D34-8043-431B9051B3EA
P2860
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacological inhibition of ...... ammatory pathway linked to NAD
@ast
Pharmacological inhibition of ...... ammatory pathway linked to NAD
@en
Pharmacological inhibition of ...... mmatory pathway linked to NAD.
@nl
type
label
Pharmacological inhibition of ...... ammatory pathway linked to NAD
@ast
Pharmacological inhibition of ...... ammatory pathway linked to NAD
@en
Pharmacological inhibition of ...... mmatory pathway linked to NAD.
@nl
prefLabel
Pharmacological inhibition of ...... ammatory pathway linked to NAD
@ast
Pharmacological inhibition of ...... ammatory pathway linked to NAD
@en
Pharmacological inhibition of ...... mmatory pathway linked to NAD.
@nl
P2093
P2860
P1433
P1476
Pharmacological inhibition of ...... ammatory pathway linked to NAD
@en
P2093
Alexander So
Aline Rolaz
Frédéric Van Gool
Mahir Karababa
Mara Galli
Massimo Nobile
Nathalie Busso
Oberdan Leo
Thibaut De Smedt
P2860
P356
10.1371/JOURNAL.PONE.0002267
P407
P577
2008-05-21T00:00:00Z